Author

Shuai Wang

Howard Hughes Medical InstituteORCID 0000-0002-9142-6095Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Shuai Wang7 papers · BGI Group (China)

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Adam Daniels· 1 shared Andrew S. LemoffiD· 1 shared Ann Marie FluschéiD· 1 shared Apolonia GardneriD· 1 shared Ashley Carter· 1 shared Bingnan Wang· 1 shared Chiho KimiD· 1 shared Christin M. HongiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Adam Daniels

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

AAV NRF2 Gene Therapy Preserves Retinal Structure and Function in Rodent Models of Oxidative Damage

Apolonia Gardner, Shuai Wang, Adam Daniels, Dan Dan Li, Christine C. Wu, Lucas Lin, Christin M. Hong, Sophia R. Zhao, Richard T. Born, Kamil Kruczek, Genevieve Weist, Laura Barrio Real, Joan Wicks, Mohamad Nayal, Ashley Carter, , Constance L. Cepko

This paper tests AAV8/Best1-Nrf2 gene therapy in rodent models of oxidative stress, showing protection of retinal cells and preservation of visual function.

Molecular Therapy · Feb 6, 2026Peer-reviewedPharmacology & Toxicology

Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in cancer

Qian Wang, Liping Li, Lin You, Shuai Wang, Lei Han, Bingnan Wang, Liping Yao, Yesu Addepalli, Yong De Lu, Ilgen Mender, Ann Marie Flusché, Chiho Kim, Nageswari Yarravarapu, Andrew S. Lemoff, Lawrence Lum, , Chuo Chen

This study shows that degrading tankyrase (TNKS) with PROTACs overcomes the limitations of catalytic inhibitors by preventing AXIN puncta formation and enhancing WNT/β-catenin pathway suppression in colorectal cancer.

bioRxiv · Sep 22, 2025 · PreprintCancer Biology